Phase II Exploratory Clinical Study of KUX-1151
NCT02190786 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL
Last updated 2015-10-19
Summary
The purpose of this study is to investigate the efficacy, safety and pharmacokinetics of multiple oral administration of KUX-1151 in patients with hyperuricemia including gout.
Conditions
- Hyperuricemia
Interventions
- DRUG
-
KUX-1151
Sponsors & Collaborators
-
Kissei Pharmaceutical Co., Ltd.
lead INDUSTRY
Eligibility
- Min Age
- 20 Years
- Max Age
- 64 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Primary Completion
- 2015-03-31
Countries
- Japan
More Related Trials
-
Study of FYU-981 in Hyperuricemia With or Without Gout
NCT02416167 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Trial of HR091506 Tablets in Treatment of Gout With Hyperuricemia in Adults
NCT06414837 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Phase 2 Study of URC102 to Assess the Efficacy and Safety in Gout Patients
NCT02290210 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Assess the Safety and Tolerability of SSS11 in Healthy Subjects.
NCT03388515 ·Status: UNKNOWN ·Phase: PHASE1
-
Evaluate the PK, PD, and Safety of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Patients With Gout
NCT02252835 ·Status: COMPLETED ·Phase: PHASE2
-
Study of URC102 to Assess the Safety and Efficacy in Gout Patients
NCT02557126 ·Status: COMPLETED ·Phase: PHASE2
-
Dose-Response, Safety and Efficacy of Febuxostat in Subjects With Gout
NCT00174967 ·Status: COMPLETED ·Phase: PHASE2
-
Study of FYU-981 in Hyperuricemia With or Without Gout
NCT03006445 ·Status: COMPLETED ·Phase: PHASE3
-
Tolerance, Pharmacokinetics / Pharmacodynamics (PK / PD) and Immunogenicity of Pegylated Uric Acid Oxidase for Injection in Healthy Adults and Hyperuricemia Volunteers
NCT05226013 ·Status: UNKNOWN ·Phase: PHASE1
-
Phase II Dose Finding Study of RDEA3170 Versus Placebo in Japanese Patients With Gout or Asymptomatic Hyperuricemia
NCT02078219 ·Status: COMPLETED ·Phase: PHASE2
-
Febuxostat-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout
NCT03372200 ·Status: COMPLETED ·Phase: PHASE3
-
A PD/Safety Study of RDEA3170 in Combination With Febuxostat for Treating Gout or Asymptomatic Hyperuricemia Patients
NCT02317861 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study to Evaluate the Urate-Lowering Activity and Safety of Oral BCX4208 Administered in Subjects With Gout
NCT00985127 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy Study of MBX-102 in Treatment of Hyperuricemia in Patients With Gout
NCT01336686 ·Status: COMPLETED ·Phase: PHASE2
-
A Trial of HR091506 Tablets in Treatment of Primary Gout With Hyperuricemia in Adults
NCT05347498 ·Status: UNKNOWN ·Phase: PHASE1
-
Open Label Safety/Efficacy Study of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Gout Patients
NCT01416402 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Kui-Yuan Chewable Tablets in Patients With Hyperuricemia
NCT05913310 ·Status: UNKNOWN ·Phase: PHASE4
-
A Study of RDEA806 in Hyperuricemic Subjects With Symptomatic Gout
NCT00741442 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of Oral Febuxostat in Subjects With Gout
NCT02082769 ·Status: COMPLETED ·Phase: PHASE3
-
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
NCT01508702 ·Status: COMPLETED ·Phase: PHASE3
-
Safety, Tolerability, and Pharmacokinetic Characteristics of SSS11 in Patients With Gout and Hyperuricemia
NCT06629376 ·Status: RECRUITING ·Phase: PHASE1
-
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
NCT01082640 ·Status: COMPLETED ·Phase: PHASE2
-
RDEA3170 and Febuxostat Combination Study in Gout Subjects
NCT02246673 ·Status: COMPLETED ·Phase: PHASE2
-
Combination Treatment Study in Subjects With Tophaceous Gout With Lesinurad and Febuxostat
NCT01510769 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate Safety and Efficacy of Oral Febuxostat in Patients With Gout
NCT01736514 ·Status: COMPLETED ·Phase: PHASE3